drugset / Trial / NCT05776355
NKG2D CAR-NK & Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial will explore the maximum tolerated dose （MTD）of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.
Timeline
- Start
- 2023-03
- Primary completion
- 2024-04
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKG2D CAR-NK | Cell therapy | — | — |